NCT06079671 2026-04-02
eVOLVECervical
AstraZeneca
Phase 3 Recruiting
Clinical Trials
13 trialsNCT07473128 2026-03-16
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Pharmacosmos A/S
Phase 3 Not yet recruiting
NCT04624204 2025-07-02
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05054543 2025-06-27
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
Apollomics Inc.
Phase 3 Terminated
NCT04199689 2025-03-25
V503-049
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04571645 2024-04-15
AML
Jazz Pharmaceuticals
Phase 3 Terminated
NCT04095858 2023-02-08
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT02049151 2017-08-23
START2
EMD Serono
Phase 3 Terminated
NCT03117335 2017-04-17
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
Phase 3 Completed
NCT01015443 2016-10-26
INSPIRE
Merck KGaA, Darmstadt, Germany
Phase 3 Terminated
NCT01083615 2016-10-12
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Achieve Life Sciences
Phase 3 Terminated
NCT00925548 2014-07-24
STRIDE
EMD Serono
Phase 3 Terminated
NCT00518895 2011-11-07
AGENDA
Genta Incorporated
Phase 3 Completed